Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 18/20 | 0.56 |
| ▸ | HSD11B2 | P80365 | 8/20 | 0.56 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14680490 | 0.89 | HSD11B1 (0.55) | HSD11B1HSD11B2 | |
| SCHEMBL19529446 | 0.89 | HSD11B1 (0.51) | HSD11B1HSD11B2 | |
| SCHEMBL14680701 | 0.89 | HSD11B1 (0.51) | HSD11B1HSD11B2 | |
| SCHEMBL974113 | 0.87 | HSD11B1 (0.56) | HSD11B1HSD11B2DGAT1 | |
| SCHEMBL1847057 | 0.87 | HSD11B1 (0.56) | HSD11B1HSD11B2DGAT1 | |
| SCHEMBL974114 | 0.87 | HSD11B1 (0.56) | HSD11B1HSD11B2DGAT1 | |
| SCHEMBL12578947 | 0.87 | HSD11B1 (0.56) | HSD11B1HSD11B2DGAT1 | |
| SCHEMBL1847058 | 0.87 | HSD11B1 (0.56) | HSD11B1HSD11B2DGAT1 | |
| SCHEMBL974112 | 0.87 | HSD11B1 (0.56) | HSD11B1HSD11B2DGAT1 | |
| SCHEMBL6338618 | 0.82 | EPHX2 (0.51) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073830-B2 | Compound for inhibiting 11β-hydroxy steroid dehydrogenase 1, and a pharmaceutical composition comprising the same | HYUNDAI PHARM CO., LTD. (KR) | 2015-07-07 | — | — | US | disclosed |
| US-20140206875-A1 | A COMPOUND FOR INHIBITING 11B-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HYUNDAI PHARM CO., LTD. (KR) | 2014-07-24 | — | — | US | disclosed |
| WO-2013019091-A2 | A COMPOUND FOR INHIBITING 11β-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HYUNDAI PHARM CO., LTD. (KR) | 2013-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206875-A1 | A COMPOUND FOR INHIBITING 11B-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885HSD11B2 2/4885DGAT1 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.